Genteel, Smart Meter win DSN/ECRM Buyers' Choice Awards

6/3/2019
Genteel won the Drug Store News/ECRM Buyers Choice Award for its blood drawing device during ECRM’s Diabetes/Clinical Programs, Connected Devices & Patient Engagement Program held in Bonita Springs, Fla. last month. Smart Meter was a finalist for its iGlucose blood glucose monitoring system.

The two companies were selected from dozens of entries in the award program, samples of which were displayed in the ECRM hospitality area during the EPPS meetings. Buyers cast their votes based on product innovation and packaging.

“The two winning products are great examples of how companies are using technology innovation to promote adherence for diabetic patients,” said Michael Castillo, senior vice president of Pharmacy & Medical Markets for ECRM. “Genteel’s product removes the pain and mess of extracting blood, while Smart Meter’s iGlucose monitor enables users to easily and regularly track blood-sugar levels.”

Genteel was founded by Dr. Christopher Jacobs, a Ph.D. in Biomedical Engineering who sought to develop a blood drawing device that did not require the painful and messy pricking of fingers that is typical for blood glucose testing.

The patented Genteel is a lancing device that enables those with diabetes to have pain-free blood drop extraction anywhere on the body. It’s around the same size as most lancet holders, yet it’s the only standalone FDA cleared lancing device that can reliably retrieve a blood drop from fingers – as well as alternate sites -- using a vacuum.

Smart Meter is a medical device company that delivers real-time patient-generated data to caregivers and healthcare professionals using connected device technology. Its iGlucose diabetes management system is a state-of-the-art blood glucose sensor with built-in GSM connectivity. It is coupled with a web-based platform designed for the patient and healthcare provider and its cell-signal connectivity allows people with diabetes to seamlessly share their blood glucose readings with others, according to the company.
X
This ad will auto-close in 10 seconds